Publications by authors named "Angela Sanzo-Machuca"
Article Synopsis
- Remdesivir (RDV) was the first FDA-approved antiviral for treating severe COVID-19 by inhibiting SARS-CoV-2 replication through targeting an essential protein (nsp12) in the virus.
- In a study, 38.3% of patients showed no response to RDV treatment, with specific genetic mutations detected in non-responders, indicating possible pathways to RDV resistance.
- The findings highlight the need for ongoing monitoring of genetic variations in the virus, especially among immunosuppressed patients, to inform treatment strategies and health surveillance efforts as RDV continues to be used.
Thioredoxins (TRX) are traditionally considered as enzymes catalyzing redox reactions. However, redox-independent functions of thioredoxins have been described in different organisms, although the underlying molecular mechanisms are yet unknown. We report here the characterization of the first generated endogenous redox-inactive thioredoxin in an animal model, the TRX-1 in the nematode Caenorhabditis elegans.
View Article and Find Full Text PDF